Project Profile

Protocol TG4040.02: A Phase II Randomized, Multicenter, Open-Label Study of TG4040 (MVA-HCV) in combination with Pegylated Interferon Alfa-2A and Ribavirin versus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naive Patients with Chronic Genotype

Keyword Search